Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

Homer N.; Grewal D. S.; Mirza R. G.; Lyon A. T.; Gill M. K.

首页> 外文期刊>Eye >Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

【24h】

Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

机译：对以下问题的回复：“关于在新血管性年龄相关性黄斑变性中采用既往治疗和延长剂量方案后过渡到玻璃体内阿柏西普的评论：24个月的结果”

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Eye》 |2015年第12期|共3页
作者
Homer N.; Grewal D. S.; Mirza R. G.; Lyon A. T.; Gill M. K.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results' [J] . Homer N., Grewal D. S., Mirza R. G., Eye . 2015,第12期

机译：对以下问题的回复：“关于在新血管性年龄相关性黄斑变性中采用既往治疗和延长剂量方案后过渡到玻璃体内阿柏西普的评论：24个月的结果”
2. Comment on 'Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results' [J] . Dave V. P. Eye . 2015,第12期

机译：评论“在以前的治疗和延长剂量方案后，新血管性年龄相关性黄斑变性患者过渡为玻璃体内阿柏西普：24个月的结果”
3. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results [J] . Homer N., Grewal D. S., Mirza R. G., Eye . 2015,第9期

机译：在先前的治疗和延伸剂量相关黄斑变性中的治疗和延伸给药方案后过渡到玻璃体内αpercept：24个月的结果
4. Assessment of Choroidal Neovascular Membranes Secondary to Age-Related Macular Degeneration Using Feature Selection [C] . E. Brankin, P.J. McCullagh, W.P. Patton European Conference of the International Federation for Medical and Biological Engineering . 2013

机译：用特征选择评估二次与年龄相关黄斑变性的脉络膜新生血管膜
5. Arterial Thromboembolic Events following Intravitreal Vascular Endothelial Growth Factor Inhibitor Therapy for Age-Related Macular Degeneration in Regular Clinical Practice. [D] . Fafowora, Oluwatoyin Folasade. 2015

机译：在常规临床实践中，玻璃体内血管内皮生长因子抑制剂治疗与年龄相关的黄斑变性的动脉血栓栓塞事件。
6. Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results [O] . N Homer, D S Grewal, R G Mirza, 2015

机译：对以下问题的回应：关于在新血管性年龄相关性黄斑变性中采用既往治疗和延长剂量方案后过渡至玻璃体内阿柏西普的评论：24个月的结果
7. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR [O] . Masahito Ohji, Kanji Takahashi, Annabelle A. Okada, 2020

机译：玻璃体玻璃纤维上的疗效和安全性在渗出性年龄相关黄斑变性中的治疗和延伸方案：52-和96周的Altair发现

Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

著录项

相似文献

相关主题

期刊订阅